Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for acute myelogenous leukemia.

R L Powles, T A Lister, D Crowther

    Bibliotheca Haematologica
    |January 1, 1975
    PubMed
    Summary

    Adding immunotherapy to chemotherapy significantly improved survival rates for acute myelogenous leukemia (AML) patients. This immunotherapy approach, using irradiated AML cells and BCG, demonstrated a notable increase in patient survival and remission duration.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours.

    British journal of cancer·2011
    Same author

    Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men.

    The journals of gerontology. Series A, Biological sciences and medical sciences·2011
    Same author

    Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

    British medical journal·2010
    Same author

    Clinical validation of an autoantibody test for lung cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2010
    Same author

    The diagnosis of soft tissue tumours: Invited comment.

    Annals of the Royal College of Surgeons of England·2009
    Same author

    Reproduction and development of laboratory and wild house dust mites (Acari: Pyroglyphidae) and their relationship to the natural dust ecosystem.

    Journal of medical entomology·2007

    Area of Science:

    • Oncology
    • Immunology
    • Hematology

    Background:

    • Acute myelogenous leukemia (AML) is a serious hematologic malignancy.
    • Standard chemotherapy can induce remission but relapse is common.
    • Novel therapeutic strategies are needed to improve long-term outcomes in AML.

    Purpose of the Study:

    • To evaluate the efficacy of immunotherapy combined with chemotherapy in patients with acute myelogenous leukemia.
    • To compare survival and remission duration between chemotherapy alone and chemotherapy plus immunotherapy.

    Main Methods:

    • A randomized trial involving 107 untreated AML patients.
    • Patients received induction chemotherapy, and those achieving remission were randomized to chemotherapy alone or chemotherapy with immunotherapy (irradiated AML cells and BCG).

    Related Experiment Videos

  • Survival and remission lengths were compared between the two groups.

    • Main Results:

    • Patients receiving chemotherapy plus immunotherapy showed significantly longer median survival (545 days) compared to chemotherapy alone (303 days).
    • The immunotherapy group also had a longer median remission duration (312 days) versus chemotherapy alone (188 days).
    • The difference in survival between the groups was statistically significant (sigma = 0.003).

    Conclusions:

    • Combining immunotherapy with chemotherapy offers a significant survival benefit for acute myelogenous leukemia patients in remission.
    • Immunotherapy, utilizing irradiated AML cells and BCG, appears to be a promising adjuvant treatment for AML.
    • Further research into immunotherapy combinations may improve long-term prognosis for AML patients.